Tox | Related Drugs | BioActivity |

Stem definition	Drug id	CAS RN
angiotensin-converting enzyme inhibitors	2340	85441-61-8

Description:

Molecule	Description
Molfile Inchi Smiles Synonyms: quinapril ectren koretic quinapril hydrochloride quinapril HCl	A tetrahydroisoquinoline derivative and ANGIOTENSIN CONVERTING ENZYME inhibitor that is used in the treatment of HYPERTENSION and HEART FAILURE. Molecular weight: 438.52 Formula: C25H30N2O5 CLOGP: 1.74 LIPINSKI: 0 HAC: 7 HDO: 2 TPSA: 95.94 ALOGS: -4.71 ROTB: 10 Status: OFP Legend: OFP - off patent OFM - off market ONP - on patent

Molecule

Description

Molfile Inchi Smiles

Synonyms:

quinapril
ectren
koretic
quinapril hydrochloride
quinapril HCl

A tetrahydroisoquinoline derivative and ANGIOTENSIN CONVERTING ENZYME inhibitor that is used in the treatment of HYPERTENSION and HEART FAILURE.

Molecular weight: 438.52
Formula: C25H30N2O5
CLOGP: 1.74
LIPINSKI: 0
HAC: 7
HDO: 2
TPSA: 95.94
ALOGS: -4.71
ROTB: 10

Status: OFP

Legend:
OFP - off patent
OFM - off market
ONP - on patent

Drug dosage:

Dose	Unit	Route
15	mg	O
15	mg	P

ADMET properties:

Property	Value	Reference
BDDCS (Biopharmaceutical Drug Disposition Classification System)	1	Bocci G, Oprea TI, Benet LZ
S (Water solubility)	0.00 mg/mL	Benet LZ, Broccatelli F, Oprea TI
EoM (Fraction excreted unchanged in urine)	3.10 %	Benet LZ, Broccatelli F, Oprea TI
MRTD (Maximum Recommended Therapeutic Daily Dose)	2.61 µM/kg/day	Contrera JF, Matthews EJ, Kruhlak NL, Benz RD
BA (Bioavailability)	50 %	Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H

Predicted pharmacokinetic/toxicological properties (PK-AZ):

Property	Description	Value	Unit	Confidence	Similarity
azlogd74	LogD at pH 7.4	0.509		High	1
caco2-efflux	Caco-2 efflux ratio (BA/AB)	6.397		High	1
caco2-intrinsic-papp	Caco-2 intrinsic apparent permeability	3.451	10^-6 cm/s	High	1
dh-clint	Dog hepatocyte intrinsic clearance	14.125	uL/min/10^6 cells	High	1
dppb	Dog plasma protein binding (% unbound)	4.100	%	High	1
fcs-ppb	Fetal calf serum protein binding (% unbound)	6.180	%	High	1
herg	hERG pIC50	4.284	pIC50	High	1
hh-clint	Human hepatocyte intrinsic clearance	38.019	uL/min/10^6 cells	High	1
hlm-clint	Human liver microsomal intrinsic clearance	41.783	uL/min/mg protein	High	1
hppb	Human plasma protein binding (% unbound)	4.990	%	High	1
kinase-safety-class	ACVR2A,ACVR2B,AXL,BRAF,BTK,CAMK2D,CDK5,CDK9,DYRK1B,EIF2AK3,EPHB4,ERBB2,GRK2,ITK,MAP2K6,MAP3K7,MAPK7,MAPKAPK2,NTRK2,PDK1,PDK2,PDK4,PIK3CB,PRKDC,SYK,TEK,TGFBR1	27
kinase-selectivity-class	AXL,BRAF,EPHB4,GRK2,MAP2K6,PDK4	6
mdck-mdr1-bcrp-efflux	MDCK-MDR1-BCRP efflux ratio	2.393		Moderate	0.69
mdck-mdr1-efflux	MDCK-MDR1 efflux ratio	1.862		High	1
mh-clint	Mouse hepatocyte intrinsic clearance	51.642		High	1
mppb	Mouse plasma protein binding (% unbound)	3.890		High	1
nih-mdck-mdr1-efflux	NIH MDCK-MDR1 efflux ratio	9.268		High	1
pfas-class	PFAS structural alert (1 = True, 0 = False)	0
pld-class	Phospholipidosis risk class (1 = positive, 0 = negative)	0		Moderate	0.66
pppb	Pig plasma protein binding (% unbound)	7.170	%	High	1
rat-kpuu-brain	Rat brain Kpuu	0.008	%	Moderate	0.69
rh-clint	Rat hepatocyte intrinsic clearance	115.080	uL/min/10^6 cells	High	1
rh-fuinc	Rat hepatocyte fraction unbound in incubation	68.980	%	High	1
rppb	Rat plasma protein binding (% unbound)	3.190	%	High	1
solubility-dd	Solubility at pH 7.4 in DMSO	931.108	uM	High	1

Approvals:

Date	Agency	Company	Orphan
Nov. 19, 1991	FDA	PFIZER PHARMS

FDA Adverse Event Reporting System (Female)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Creatinine renal clearance decreased	1370.63	22.09	350	12214	18549	90597334
Sedation complication	1363.42	22.09	341	12223	16603	90599280
Orthostatic hypotension	1356.97	22.09	412	12152	41415	90574468
Sedation	1229.37	22.09	395	12169	47776	90568107
Blood calcium decreased	1208.31	22.09	350	12214	29832	90586051
Cognitive disorder	1155.80	22.09	413	12151	68994	90546889
Balance disorder	1034.78	22.09	417	12147	96663	90519220
Depressed level of consciousness	913.12	22.09	352	12212	72432	90543451
Constipation	641.26	22.09	427	12137	279968	90335915
Hypotension	588.31	22.09	429	12135	324968	90290915
Fall	578.84	22.09	499	12065	481311	90134572
Toxicity to various agents	480.35	22.09	362	12202	287484	90328399
Mobility decreased	476.18	22.09	341	12223	250393	90365490
Creatinine renal clearance increased	171.52	22.09	47	12517	3234	90612649
Renal function test abnormal	154.73	22.09	52	12512	7139	90608744
Pain	151.30	22.09	386	12178	995955	89619928
Multiple drug therapy	144.17	22.09	49	12515	6960	90608923
Heart sounds	117.05	22.09	28	12536	1116	90614767
Prolonged expiration	114.43	22.09	28	12536	1229	90614654
Depressive symptom	78.44	22.09	29	12535	5256	90610627
Respiration abnormal	66.92	22.09	29	12535	7934	90607949
Hypertensive emergency	63.83	22.09	20	12544	2197	90613686
Appetite disorder	63.11	22.09	29	12535	9104	90606779
Cardiac failure congestive	48.52	22.09	64	12500	98630	90517253
Rales	45.52	22.09	28	12536	15799	90600084
Flank pain	45.33	22.09	30	12534	19192	90596691
Angina pectoris	39.48	22.09	37	12527	39123	90576760
Myocardial infarction	39.20	22.09	60	12504	105912	90509971
Drug ineffective	38.15	22.09	85	12479	1384213	89231670
Drug abuse	36.82	22.09	51	12513	82296	90533587
Arthropathy	34.27	22.09	5	12559	366237	90249646
Synovitis	32.04	22.09	4	12560	329748	90286135
Rash	31	22.09	39	12525	796061	89819822
Bladder disorder	30.83	22.09	19	12545	10753	90605130
Dementia	28.89	22.09	25	12539	23836	90592047
Hepatic enzyme increased	27.42	22.09	8	12556	360728	90255155
Glossodynia	26.63	22.09	6	12558	321773	90294110
Therapeutic product effect decreased	25.47	22.09	4	12560	277567	90338316
Alopecia	25.33	22.09	19	12545	495052	90120831
Hypersensitivity	25.18	22.09	16	12548	454661	90161222
Discomfort	25.07	22.09	4	12560	274331	90341552
General physical health deterioration	25.00	22.09	9	12555	355106	90260777
Decreased activity	24.86	22.09	15	12549	8177	90607706
Drug interaction	23.57	22.09	88	12476	276365	90339518
Cerebrovascular accident	22.93	22.09	52	12512	123481	90492402
Exposure during pregnancy	22.89	22.09	3	12561	238407	90377476
Overdose	22.49	22.09	60	12504	157649	90458234
Impaired healing	22.36	22.09	3	12561	234196	90381687
Productive cough	22.22	22.09	39	12525	77024	90538859

FDA Adverse Event Reporting System (Male)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Blood mercury abnormal	139.56	18.51	25	5226	257	42615827
Low density lipoprotein decreased	101.40	18.51	25	5226	1279	42614805
Expired product administered	92.66	18.51	30	5221	4133	42611951
Hepatic neoplasm	88.54	18.51	25	5226	2166	42613918
5-hydroxyindolacetic acid in urine increased	87.83	18.51	16	5235	182	42615902
Cardiac failure congestive	71.48	18.51	69	5182	85533	42530551
Head titubation	68.47	18.51	15	5236	454	42615630
Neoplasm	66.12	18.51	26	5225	6279	42609805
Glycosylated haemoglobin increased	56.83	18.51	29	5222	12895	42603189
Myocardial infarction	56.77	18.51	73	5178	123936	42492148
5-hydroxyindolacetic acid increased	48.95	18.51	9	5242	108	42615976
Cogwheel rigidity	48.45	18.51	15	5236	1786	42614298
Blood glucose increased	48.01	18.51	52	5199	73647	42542437
Arteriosclerosis coronary artery	46.85	18.51	29	5222	18648	42597436
Blood follicle stimulating hormone increased	43.12	18.51	9	5242	215	42615869
Hypertensive emergency	40.00	18.51	12	5239	1285	42614799
Blood potassium decreased	39.69	18.51	27	5224	20357	42595727
Fibrous histiocytoma	38.97	18.51	9	5242	347	42615737
Angioedema	36.83	18.51	35	5216	42442	42573642
Haematocrit decreased	36.60	18.51	32	5219	34876	42581208
Renal phospholipidosis	34.31	18.51	7	5244	149	42615935
Sedation complication	34.01	18.51	13	5238	2906	42613178
Gamma-glutamyltransferase increased	32.49	18.51	29	5222	32468	42583616
Blood pressure systolic increased	30.04	18.51	26	5225	27942	42588142
Acute myocardial infarction	29.36	18.51	36	5215	58129	42557955
Red blood cell count decreased	28.43	18.51	27	5224	32688	42583396
Urticaria	28.34	18.51	40	5211	73996	42542088
Coronary artery disease	28.33	18.51	34	5217	53686	42562398
Extrapyramidal disorder	25.62	18.51	19	5232	16393	42599691
Syncope	24.62	18.51	44	5207	99362	42516722
Rhabdomyolysis	23.92	18.51	38	5213	77981	42538103
Pseudohyponatraemia	23.40	18.51	5	5246	134	42615950
Bronchomalacia	22.46	18.51	5	5246	163	42615921
Cardiopulmonary failure	22.01	18.51	11	5240	4672	42611412
Anticholinergic syndrome	21.88	18.51	8	5243	1581	42614503
Paralysis	20.44	18.51	12	5239	7008	42609076
Aspartate aminotransferase increased	20.19	18.51	35	5216	77128	42538956

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Sedation complication	1387.55	18.53	362	16002	19493	110553442
Creatinine renal clearance decreased	1330.08	18.53	357	16007	21458	110551477
Orthostatic hypotension	1169.39	18.53	419	15945	65830	110507105
Blood calcium decreased	1167.53	18.53	360	16004	35485	110537450
Sedation	1081.97	18.53	401	15963	69282	110503653
Cognitive disorder	1062.84	18.53	421	15943	87090	110485845
Balance disorder	956.03	18.53	424	15940	116136	110456799
Depressed level of consciousness	767.56	18.53	360	16004	111918	110461017
Constipation	530.13	18.53	431	15933	357355	110215580
Mobility decreased	525.52	18.53	364	16000	237058	110335877
Fall	493.00	18.53	521	15843	602961	109969974
Hypotension	461.18	18.53	471	15893	523378	110049557
Toxicity to various agents	337.73	18.53	384	15980	480171	110092764
Pain	170.29	18.53	410	15954	954545	109618390
Creatinine renal clearance increased	163.84	18.53	47	16317	3578	110569357
Renal function test abnormal	140.28	18.53	52	16312	8894	110564041
Blood mercury abnormal	134.95	18.53	25	16339	257	110572678
Multiple drug therapy	134.60	18.53	49	16315	7965	110564970
Heart sounds	115.25	18.53	28	16336	1115	110571820
Cardiac failure congestive	107.74	18.53	122	16242	150878	110422057
Prolonged expiration	106.75	18.53	28	16336	1524	110571411
Hypertensive emergency	97.72	18.53	31	16333	3320	110569615
Low density lipoprotein decreased	94.67	18.53	25	16339	1397	110571538
Myocardial infarction	87.37	18.53	124	16240	191959	110380976
5-hydroxyindolacetic acid in urine increased	84.72	18.53	16	16348	184	110572751
Expired product administered	73.51	18.53	32	16332	8288	110564647
Hepatic neoplasm	70.02	18.53	25	16339	3842	110569093
Depressive symptom	63.57	18.53	29	16335	8385	110564550
Respiration abnormal	62.34	18.53	30	16334	9779	110563156
Appetite disorder	59.44	18.53	29	16335	9740	110563195
5-hydroxyindolacetic acid increased	45.95	18.53	9	16355	127	110572808
Neoplasm	44.75	18.53	25	16339	11062	110561873
Angina pectoris	43.81	18.53	50	16314	62245	110510690
Glycosylated haemoglobin increased	42.38	18.53	32	16332	23587	110549348
Flank pain	40.76	18.53	31	16333	23099	110549836
Coronary artery disease	39.74	18.53	51	16313	71639	110501296
Arteriosclerosis coronary artery	38.50	18.53	31	16333	25087	110547848
Bladder disorder	36.67	18.53	22	16342	11115	110561820
Blood follicle stimulating hormone increased	36.04	18.53	9	16355	402	110572533
Rales	34.70	18.53	29	16335	24710	110548225
Neutropenia	34.02	18.53	7	16357	374613	110198322
Drug ineffective	33.19	18.53	115	16249	1520425	109052510
General physical health deterioration	32.83	18.53	11	16353	425284	110147651
Blood glucose increased	32.58	18.53	65	16299	132431	110440504
Off label use	32.37	18.53	114	16250	1500071	109072864
Angioedema	31.35	18.53	54	16310	98446	110474489
Fibrous histiocytoma	29.68	18.53	9	16355	830	110572105
Head titubation	29.28	18.53	10	16354	1347	110571588
Cerebrovascular accident	27.98	18.53	74	16290	181210	110391725
Synovitis	27.33	18.53	4	16360	274088	110298847
Arthropathy	26.88	18.53	5	16359	287517	110285418
Renal phospholipidosis	26.51	18.53	7	16357	391	110572544
Acute myocardial infarction	25.45	18.53	45	16319	83732	110489203
Red blood cell count decreased	24.83	18.53	39	16325	65884	110507051
Blood potassium decreased	24.65	18.53	35	16329	54079	110518856
Condition aggravated	24.16	18.53	45	16319	734791	109838144
Rash	23.84	18.53	54	16310	820910	109752025
Dementia	23.25	18.53	26	16338	31647	110541288
Febrile neutropenia	23.06	18.53	9	16355	316758	110256177
Infection	22.23	18.53	13	16351	362187	110210748
Haematocrit decreased	22.03	18.53	37	16327	66080	110506855
Depressed mood	21.56	18.53	35	16329	60774	110512161
Allergy to arthropod bite	21.17	18.53	6	16358	437	110572498
Systemic lupus erythematosus	20.65	18.53	6	16358	254332	110318603
Pseudohyponatraemia	20.48	18.53	5	16359	203	110572732
Decreased activity	19.98	18.53	15	16349	10959	110561976
Cogwheel rigidity	19.61	18.53	10	16354	3688	110569247
Hepatic enzyme increased	19.02	18.53	12	16352	320880	110252055

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

Source	Code	Description
ATC	C09AA06	CARDIOVASCULAR SYSTEM AGENTS ACTING ON THE RENIN-ANGIOTENSIN SYSTEM ACE INHIBITORS, PLAIN ACE inhibitors, plain
ATC	C09BA06	CARDIOVASCULAR SYSTEM AGENTS ACTING ON THE RENIN-ANGIOTENSIN SYSTEM ACE INHIBITORS, COMBINATIONS ACE inhibitors and diuretics
FDA MoA	N0000000181	Angiotensin-converting Enzyme Inhibitors
FDA EPC	N0000175562	Angiotensin Converting Enzyme Inhibitor
MeSH PA	D000806	Angiotensin-Converting Enzyme Inhibitors
MeSH PA	D000959	Antihypertensive Agents
MeSH PA	D002317	Cardiovascular Agents
MeSH PA	D004791	Enzyme Inhibitors
MeSH PA	D011480	Protease Inhibitors
CHEBI has role	CHEBI:35457	EC 3.4.15.1 (peptidyl-dipeptidase A) inhibitor
CHEBI has role	CHEBI:35526	hypoglycemic agent
CHEBI has role	CHEBI:35674	antihypertensive agent
CHEBI has role	CHEBI:50266	prodrug
CHEBI has role	CHEBI:35554	cardiovascular drug
CHEBI has role	CHEBI:35620	vasodilator agent

Related Drugs by ATC class:

C09AA ACE inhibitors, plain 15 drugs

benazepril captopril cilazapril delapril enalapril fosinopril imidapril lisinopril moexipril perindopril ramipril spirapril show all 15 →

C09BA ACE inhibitors and diuretics 11 drugs

benazepril captopril cilazapril delapril enalapril fosinopril lisinopril moexipril perindopril ramipril zofenopril

Drug Use | Suggest Off label Use Form| |View source of the data|

Disease	Relation	SNOMED_ID	DOID
Hypertensive disorder	indication	38341003	DOID:10763
Chronic heart failure	indication	48447003
Atrial fibrillation	off-label use	49436004	DOID:0060224
Diabetic renal disease	off-label use	127013003
Acute scleroderma renal crisis	off-label use	236503001
Diastolic heart failure	off-label use	418304008	DOID:9775
Nondiabetic Proteinuric Nephropathy	off-label use
Anuria	contraindication	2472002	DOID:2983
Hypercholesterolemia	contraindication	13644009
Hyperkalemia	contraindication	14140009
Secondary angle-closure glaucoma	contraindication	21571006
Hypovolemia	contraindication	28560003
Acute cerebrovascular insufficiency	contraindication	29322000
Dehydration	contraindication	34095006
Hyperuricemia	contraindication	35885006	DOID:1920
Immunosuppression	contraindication	38013005
Angioedema	contraindication	41291007	DOID:1558
Hypokalemia	contraindication	43339004
Low blood pressure	contraindication	45007003
Systemic lupus erythematosus	contraindication	55464009	DOID:9074
Sympathectomy	contraindication	57071006
Hypercalcemia	contraindication	66931009	DOID:12678
Hyperparathyroidism	contraindication	66999008	DOID:13543
Hypochloremic alkalosis	contraindication	70134007
Hepatic coma	contraindication	72836002	DOID:12550
Diabetes mellitus	contraindication	73211009	DOID:9351
Hereditary angioneurotic edema	contraindication	82966003	DOID:14735
Hyponatremia	contraindication	89627008
Gout	contraindication	90560007	DOID:13189
Kidney disease	contraindication	90708001	DOID:557
Disorder of connective tissue	contraindication	105969002	DOID:65
Hypomagnesemia	contraindication	190855004
Acute pancreatitis	contraindication	197456007	DOID:2913
Disease of liver	contraindication	235856003	DOID:409
Neonatal hyperbilirubinemia	contraindication	281610001
Pregnancy, function	contraindication	289908002
Renal artery stenosis	contraindication	302233006
Neutropenic disorder	contraindication	303011007	DOID:1227
Bone marrow depression	contraindication	307762000
Myocardial ischemia	contraindication	414795007	DOID:3393
Azotemia	contraindication	445009001
Hemodialysis with High-Flux Membrane	contraindication

🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation level	Dissociation constant	Type (acidic/basic)
pKa1	2.96	acidic
pKa2	5.72	Basic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

Target	Class	Pharos	UniProt	Action	Type	Activity value (-log[M])	Mechanism action	Bioact source	MoA source
Angiotensin-converting enzyme	Enzyme	P12821	ACE_HUMAN	INHIBITOR	IC50	8.08		CHEMBL	CHEMBL
Angiotensin-converting enzyme	Enzyme		ACE_RABIT		IC50	5.40		DRUG MATRIX

External reference:

ID	Source
4020549	VUID
N0000148256	NUI
D00459	KEGG_DRUG
82586-55-8	SECONDARY_CAS_RN
4020379	VANDF
4020549	VANDF
C0072857	UMLSCUI
CHEBI:8713	CHEBI
CHEMBL1592	ChEMBL_ID
CHEMBL1201011	ChEMBL_ID
D000077583	MESH_DESCRIPTOR_UI
DB00881	DRUGBANK_ID
6350	IUPHAR_LIGAND_ID
5780	INN_ID
RJ84Y44811	UNII
54892	PUBCHEM_CID
DB14217	DRUGBANK_ID
1546359	RXNORM
5401	MMSL
63990	MMSL
d00365	MMSL
003612	NDDF
003613	NDDF
108578004	SNOMEDCT_US
386874003	SNOMEDCT_US
386875002	SNOMEDCT_US
C0072858	UMLSCUI
CHEMBL1733	ChEMBL_ID
82768-85-2	SECONDARY_CAS_RN
107994	PUBCHEM_CID
6352	IUPHAR_LIGAND_ID
6356	INN_ID
C054501	MESH_SUPPLEMENTAL_RECORD_UI
34SSX5LDE5	UNII
CHEBI:140296	CHEBI
34SSX5LDE5	INXIGHT DRUGS
RJ84Y44811	INXIGHT DRUGS

Pharmaceutical products:

Product	Category	Ingredients	NDC	Form	Quantity	Route	Marketing	Label
Quinapril	HUMAN PRESCRIPTION DRUG LABEL	1	21695-393	TABLET	5 mg	ORAL	ANDA	24 sections
Quinapril	HUMAN PRESCRIPTION DRUG LABEL	1	21695-394	TABLET	10 mg	ORAL	ANDA	24 sections
Quinapril	HUMAN PRESCRIPTION DRUG LABEL	1	31722-267	TABLET	5 mg	ORAL	ANDA	22 sections
Quinapril	HUMAN PRESCRIPTION DRUG LABEL	1	31722-268	TABLET	10 mg	ORAL	ANDA	22 sections
Quinapril	HUMAN PRESCRIPTION DRUG LABEL	1	31722-269	TABLET	20 mg	ORAL	ANDA	22 sections
Quinapril	HUMAN PRESCRIPTION DRUG LABEL	1	31722-270	TABLET	40 mg	ORAL	ANDA	22 sections
Quinapril Hydrochloride and Hydrochlorothiazide	HUMAN PRESCRIPTION DRUG LABEL	2	31722-374	TABLET	10 mg	ORAL	ANDA	23 sections
Quinapril Hydrochloride and Hydrochlorothiazide	HUMAN PRESCRIPTION DRUG LABEL	2	31722-375	TABLET	20 mg	ORAL	ANDA	23 sections
Quinapril Hydrochloride and Hydrochlorothiazide	HUMAN PRESCRIPTION DRUG LABEL	2	31722-376	TABLET	20 mg	ORAL	ANDA	23 sections
Quinapril HCL and Hydrochlorothiazide	HUMAN PRESCRIPTION DRUG LABEL	2	43386-710	TABLET	10 mg	ORAL	ANDA	12 sections
Quinapril HCL and Hydrochlorothiazide	HUMAN PRESCRIPTION DRUG LABEL	2	43386-711	TABLET	20 mg	ORAL	ANDA	12 sections
Quinapril HCL and Hydrochlorothiazide	HUMAN PRESCRIPTION DRUG LABEL	2	43386-712	TABLET	20 mg	ORAL	ANDA	12 sections
QUINAPRIL	HUMAN PRESCRIPTION DRUG LABEL	1	43547-410	TABLET	5 mg	ORAL	ANDA	13 sections
QUINAPRIL	HUMAN PRESCRIPTION DRUG LABEL	1	43547-411	TABLET	10 mg	ORAL	ANDA	13 sections
QUINAPRIL	HUMAN PRESCRIPTION DRUG LABEL	1	43547-412	TABLET	20 mg	ORAL	ANDA	13 sections
QUINAPRIL	HUMAN PRESCRIPTION DRUG LABEL	1	43547-413	TABLET	40 mg	ORAL	ANDA	13 sections
Quinapril	Human Prescription Drug Label	1	50090-2116	TABLET, FILM COATED	20 mg	ORAL	ANDA	20 sections
Quinapril	Human Prescription Drug Label	1	50090-2117	TABLET, FILM COATED	40 mg	ORAL	ANDA	20 sections
Quinapril	HUMAN PRESCRIPTION DRUG LABEL	1	50090-4649	TABLET	40 mg	ORAL	ANDA	13 sections
Quinapril	HUMAN PRESCRIPTION DRUG LABEL	1	51655-737	TABLET	40 mg	ORAL	ANDA	12 sections
Quinapril Hydrochloride and Hydrochlorothiazide	HUMAN PRESCRIPTION DRUG LABEL	2	54868-1802	TABLET, FILM COATED	10 mg	ORAL	ANDA	12 sections
Quinapril Hydrochloride and Hydrochlorothiazide	HUMAN PRESCRIPTION DRUG LABEL	2	54868-2847	TABLET, FILM COATED	20 nmol	ORAL	ANDA	12 sections
Quinapril	HUMAN PRESCRIPTION DRUG LABEL	1	54868-5241	TABLET, FILM COATED	20 mg	ORAL	ANDA	12 sections
Quinapril	HUMAN PRESCRIPTION DRUG LABEL	1	54868-5245	TABLET, FILM COATED	10 mg	ORAL	ANDA	12 sections
Quinapril	HUMAN PRESCRIPTION DRUG LABEL	1	54868-5246	TABLET, FILM COATED	40 mg	ORAL	ANDA	12 sections
Quinapril	HUMAN PRESCRIPTION DRUG LABEL	1	54868-5279	TABLET, FILM COATED	5 mg	ORAL	ANDA	12 sections
Quinapril Hydrochloride and Hydrochlorothiazide	HUMAN PRESCRIPTION DRUG LABEL	2	54868-5475	TABLET, FILM COATED	20 mg	ORAL	ANDA	12 sections
Quinapril	HUMAN PRESCRIPTION DRUG LABEL	1	55111-621	TABLET	5 mg	ORAL	ANDA	19 sections
Quinapril	HUMAN PRESCRIPTION DRUG LABEL	1	55111-622	TABLET	10 mg	ORAL	ANDA	19 sections
Quinapril	HUMAN PRESCRIPTION DRUG LABEL	1	55111-623	TABLET	20 mg	ORAL	ANDA	19 sections

Ask DrugCentral

Try a sample question

quinapril 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | PK/Tox | Related Drugs | BioActivity |

Description:

Drug dosage:

ADMET properties:

Predicted pharmacokinetic/toxicological properties (PK-AZ):

Approvals:

FDA Adverse Event Reporting System (Female)

FDA Adverse Event Reporting System (Male)

FDA Adverse Event Reporting System (Geriatric)

FDA Adverse Event Reporting System (Pediatric)

Pharmacologic Action:

Related Drugs by ATC class:

Drug Use | Suggest Off label Use Form| |View source of the data|

🐶 Veterinary Drug Use

🐶 Veterinary products

Acid dissociation constants calculated using MoKa v3.0.0

Orange Book patent data (new drug applications)

Orange Book exclusivity data (new drug applications)

Bioactivity Summary:

External reference:

Pharmaceutical products: